Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAN-NeoVax in Advanced or Metastatic Solid Tumors
NCT07560943Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of PAN-NeoVax in solid tumor (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Dose-Limiting Toxicity at 3 weeks. Started Apr 2026; status: recruiting.
02
Drugs
PAN-NeoVax
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07560943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07560943.